PCA3 Reference Set Application: T2-Erg-Martin Sanda-Emory (2014)
- Abbreviated Name
- PCA3 Ref Set App-T2 ERG-Sanda (2014)
- Lead Investigator
- Sanda, Martin — Emory University
- Coordinating Investigator
- Feng, Ziding — Fred Hutchinson Cancer Center
- Involved Investigators
Abstact
Aims
Primary Specific Aims Aim 1: To validate the performance of urinary T2:erg in a multiplex model in combination with PCA3 predicting the diagnosis of histologically clinically significant prostate cancer among men without prior evidence of prostate cancer Secondary Aims Aim 1: To evaluate the sensitivity, specificity, PPV, NPV and absolute risk prediction by T2:erg/PCA3 combined and multiplexed with other biomarkers and clinical variables in the detection of histologically clinically significant prostate cancer Aim 2: To validate the performance of urinary T2:erg in a multiplex model in combination with PCA3 predicting the diagnosis of ANY prostate cancer Aim 3: To investigate whether the multiplex model performance is improved by addition of % free PSA, PSAV, -2proPSA, and other markers in development Aim 4: To evaluate the correlation between urinary and tissue based T2:erg and prostate biopsy tumor grade
Analytic Method
Transcription mediated amplification based assay
Biomarkers
Data Collections
- No data available at this time for this protocol
- Protocol ID
- 376
- Protocol Type
- Reference Set
- Field of Research
- Genomics
- Collaborative Group
- Prostate and Urologic Cancers Research Group
- Cancer Types
-
- Malignant neoplasm of prostate
- Phased Status
- 2